McKenzie, A.L., Athinarayanan, S.J
The FDA has approved Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Other Related Information Mapping in Human Pancreatic Cancer Tissue by GLP-1 (7-36)-amide Antibody (H-028-11) Protocol for antibody staining Tissue Sample Human pancreas cancer tissues Fixative 10% formalin Embedding Paraffin Negative Control No primary antibody Pretreatment N/A Blocking 3% H2O2, 2% Normal Goat Serum Primary Antibody Rabbit Anti-GLP-1 (7-36)-NH2 Antiserum (Catalog No.: H-028-11) Optimal Dilution 1: 500 Secondary Antibody Goat Anti-Rabbit IgG, Biotinylated (1:400), 30 min Amplification Streptavidin-HRP (Vector), 1:400, 30 min Detection System HRP Substrate DAB (Sigma), 3 min Counterstained Hematoxylin, 30 sec Mapping in Rat Pancreas and Intestines by GLP-1 (7-37) Antibody (H-028-13) Rat Pancreatic and intestinal tissue Pre-immuno serum Intact 2% Normal Goat Serum Rabbit Anti-GLP-1 (7-37) (Human, Rat, Mouse, Porcine) Serum (Catalog No.:H-028-13) 1:500, 1 hour at RT ABC (Vector) (1:400, 30 min) with methyl green Rat pancreatic and intestinal sections with an antiserum for human GLP-1 (737) (Phoenix Pharmaceuticals, Mountain View, California, USA) at a concentration of 1/500
This structure is described in the platform's published materials and may help inform how the program operates from intake through dispensing
doi:10.1002/osp4.84 Holst JJ
The compound tirzepatide dosing chart accounts for these variations in its calculations
